Intermediate Risk Non-Muscle Invasive Bladder Cancer research hub

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

This study is testing a new gene therapy, Nadofaragene Firadenovec, for people with a type of bladder cancer called intermediate-risk non-muscle invasive bladder cancer. It compares the new treatment to simply monitoring the cancer to see if it helps prevent recurrence.